Mota Fernando, Carvalho Sandrina, Sanches Madalena, Selores Manuela
Department of Dermatology, Porto Central Hospital, Porto, Portugal.
Dermatology Research Unit, Porto Central Hospital, Porto, Portugal.
Acta Dermatovenerol Alp Pannonica Adriat. 2016;25(1):15-7. doi: 10.15570/actaapa.2016.4.
Pityriasis rubra pilaris is a chronic inflammatory dermatosis of unknown etiology and great clinical variability. It has been divided into six categories. Types III, IV, and V occur in childhood and are distinguished by their clinical presentation, age of onset, and course. We report a 19-year-old male patient with a 2-week history of pruritic, scaling dermatosis of the hands, feet, elbows, and knees. He had no family history of skin disease. On physical examination, we observed circumscribed, reddish-orange, scaling plaques affecting the elbows and knees and a waxy palmoplantar keratoderma. The skin biopsy showed acanthosis, alternating orthokeratosis, parakeratosis, and follicular plugging suggestive of pityriasis rubra pilaris. The patient started treatment with oral acitretin, 25 mg every other day. The treatment was tolerated well, and after 6 months the lesions had resolved completely. Pityriasis rubra pilaris is a chronic papulosquamous disorder of unknown pathogenesis, characterized by reddish-orange scaly plaques, palmoplantar keratoderma, and keratotic follicular papules. There is still no consensus regarding the treatment, but therapeutic options include systemic retinoids, particularly acitretin in the recommended dose of 0.5 to 0.75 mg/kg/day. In our case, the patient was treated with a low-dose regimen of acitretin, which was effective and well tolerated.
毛发红糠疹是一种病因不明、临床表现差异很大的慢性炎症性皮肤病。它已被分为六类。III型、IV型和V型发生于儿童期,可通过临床表现、发病年龄和病程加以区分。我们报告一名19岁男性患者,有2周手部、足部、肘部和膝部瘙痒性鳞屑性皮肤病史。他没有皮肤病家族史。体格检查时,我们观察到肘部和膝部有边界清楚的红橙色鳞屑性斑块以及掌跖部蜡样角化病。皮肤活检显示棘层肥厚、正角化与角化不全交替、毛囊堵塞,提示毛发红糠疹。患者开始口服阿维A治疗,隔日25毫克。治疗耐受性良好,6个月后皮损完全消退。毛发红糠疹是一种发病机制不明的慢性丘疹鳞屑性疾病,其特征为红橙色鳞屑性斑块、掌跖角化病和角化性毛囊丘疹。关于治疗目前仍未达成共识,但治疗选择包括系统性维甲酸类药物,特别是推荐剂量为0.5至0.75毫克/千克/天的阿维A。在我们的病例中,患者接受了低剂量阿维A治疗方案,该方案有效且耐受性良好。